Zymeworks Inc. (ZYME) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ZYME Revenue Growth
Revenue Breakdown (FY 2025)
ZYME's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
ZYME Revenue Analysis (2014–2025)
As of May 8, 2026, Zymeworks Inc. (ZYME) generated trailing twelve-month (TTM) revenue of $78.9 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, ZYME's 5-year compound annual growth rate (CAGR) stands at +22.2%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $412.5 million in 2022.
Revenue diversification analysis shows ZYME's business is primarily driven by Milestone Revenue (62%), Option Exercise Fee (18%), and Research Support Payments And Other Service (14%). With over half of revenue concentrated in Milestone Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RCUS (+67.4% YoY), MRUS (+55.9% YoY), and AGIO (+78.3% YoY), ZYME has underperformed the peer group in terms of revenue growth. Compare ZYME vs RCUS →
ZYME Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ZYMECurrent | $79M | -100.0% | +22.2% | -87.3% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 MRUS | $35M | +55.9% | +4.7% | -753.0% | |
 AGIO | $54M | +78.3% | - | -873.9% |
ZYME Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $106.0M | +38.9% | $95.2M | 89.8% | $-92,549,000 | -87.3% |
| 2024 | $76.3M | +0.4% | $76.3M | 100.0% | $-137,110,000 | -179.7% |
| 2023 | $76.0M | -81.6% | $-66,977,000 | -88.1% | $-138,053,000 | -181.6% |
| 2022 | $412.5M | +1446.0% | $412.5M | 100.0% | $130.5M | 31.6% |
| 2021 | $26.7M | -31.5% | $26.7M | 100.0% | $-215,633,000 | -808.2% |
| 2020 | $39.0M | +31.8% | $-131,945,000 | -338.7% | $-187,468,000 | -481.3% |
| 2019 | $29.5M | -44.3% | $-87,552,000 | -296.3% | $-151,301,000 | -512.1% |
| 2018 | $53.0M | +2.4% | $-3,907,000 | -7.4% | $-33,127,000 | -62.5% |
| 2017 | $51.8M | +370.2% | $10.6M | 20.5% | $-8,998,000 | -17.4% |
| 2016 | $11.0M | +14.0% | $-24,542,000 | -222.9% | $-37,864,000 | -343.9% |
See ZYME's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ZYME Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ZYME vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonZYME — Frequently Asked Questions
Quick answers to the most common questions about buying ZYME stock.
Is ZYME's revenue growth accelerating or slowing?
ZYME revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of +22.2%. TTM revenue fell to $79M. This reverses the prior growth trend.
What is ZYME's long-term revenue growth rate?
Zymeworks Inc.'s 5-year revenue CAGR of +22.2% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is ZYME's revenue distributed by segment?
ZYME reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.